Quinapyramine Essence Simplified

These data prompted two large phase III clinical trials on treatment of patients with PE and on prevention of stroke and systemic embolism in patients with AF. The CASSIOPEA trial is an international, multicentre, randomized, double-blind, double-dummy study comparing 3 to 6 months treatment with idrabiotaparinux (3.0?mg subcutaneously once weekly) vs. oral INR-adjusted warfarin https://en.wikipedia.org/wiki/Quinapyramine in 3200 patients with symptomatic PE with or without symptomatic DVT. The enrolment phase has been completed and data are still to be published. The BOREALIS-AF trial is a multicentre, randomized, double-blind, non-inferiority study comparing the efficacy and safety of once weekly subcutaneous idrabiotaparinux with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolism in patients with AF. The study was prematurely stopped before completing the enrolment and the results are not yet available. Otamixaban? The parenteral direct FXa inhibitor otamixaban has a rapid onset of action, a short half-life and a limited ( http://www.selleckchem.com/products/MS-275.html with ACS who are scheduled or not for PCI [34]. The SEPIA-ACS 1- TIMI 42 trial is a phase II double-blind, triple-dummy, dose-finding study which compared five different intravenous regimens of otamixaban (0.100 to 0.140?mg?kg?1?h?1) with an active therapy of heparin plus eptifibatide for the prevention of major cardiovascular events in 3241 patients with non ST-segment elevation ACS and planned early invasive strategy [35]. Although the rate of primary efficacy outcome, a composite of death, myocardial infarction, urgent revascularization or bailout glycoprotein IIb/IIIa http://www.selleckchem.com/products/GDC-0449.html use at 7 days, did not significantly differ across the five different doses of otamixaban, or compared with the heparin plus eptifibatide arm, the rate of primary efficacy end point was lowest with the two intermediate otamixaban doses. The lowest dose of otamixaban was stopped early because of an excess of thrombotic complications. In any case the rate of thrombotic complications was numerically higher with all doses of otamixaban compared with heparin plus eptifibatide. Moreover, otamixaban was associated with a significant dose-dependent increase in the primary safety outcome of non-coronary artery bypass graft surgery-related TIMI major or minor bleeding, though bleeding rates with intermediate otamixaban doses were similar to those with heparin plus eptifibatide.